NASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $1.66 -0.11 (-6.21%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AC Immune Stock (NASDAQ:ACIU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AC Immune alerts:Sign Up Key Stats Today's Range$1.64▼$1.7950-Day Range$1.66▼$2.7552-Week Range$1.64▼$4.98Volume249,225 shsAverage Volume329,605 shsMarket Capitalization$166.68 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More… Remove Ads AC Immune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreACIU MarketRank™: AC Immune scored higher than 49% of companies evaluated by MarketBeat, and ranked 545th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days.Read more about AC Immune's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.20% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in AC Immune has recently increased by 23.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.20% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in AC Immune has recently increased by 23.85%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.80 News SentimentAC Immune has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for AC Immune this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows5 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Stock News HeadlinesAC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy RatingApril 4 at 2:57 AM | tipranks.comAC Immune SA (NASDAQ:ACIU) Short Interest Up 23.9% in MarchApril 3 at 1:25 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)AC Immune’s Strategic Advances and Financial HighlightsApril 3 at 12:18 AM | tipranks.comAC Immune announces additional data from Phase 2 study of VacSYn clinical trialApril 2 at 5:12 PM | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseApril 2 at 12:11 PM | markets.businessinsider.comAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's DiseaseApril 2 at 6:00 AM | globenewswire.comAC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025March 25, 2025 | globenewswire.comSee More Headlines ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $2.70 at the beginning of the year. Since then, ACIU shares have decreased by 38.5% and is now trading at $1.66. View the best growth stocks for 2025 here. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC). Company Calendar Last Earnings11/08/2021Today4/04/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+622.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,410,000.00 Net MarginsN/A Pretax Margin-95.58% Return on Equity-28.26% Return on Assets-18.98% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.86 Sales & Book Value Annual Sales$27.31 million Price / Sales6.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book0.78Miscellaneous Outstanding Shares100,410,000Free Float94,389,000Market Cap$166.68 million OptionableOptionable Beta1.49 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ACIU) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.